Royalty Pharma plc (RPRX) concluded trading on Wednesday at a closing price of $31.23, with 6.03 million shares of worth about $188.43 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.36% during that period and on Wednesday the price saw a gain of about 3.07%. Currently the company’s common shares owned by public are about 446.69M shares, out of which, 381.07M shares are available for trading.
Stock saw a price change of 6.55% in past 5 days and over the past one month there was a price change of 6.81%. Year-to-date (YTD), RPRX shares are showing a performance of 11.18% which decreased to -17.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $25.92 but also hit the highest price of $38.19 during that period. The average intraday trading volume for Royalty Pharma plc shares is 2.72 million. The stock is currently trading 7.19% above its 20-day simple moving average (SMA20), while that difference is up 9.40% for SMA50 and it goes to 6.01% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 446.69M outstanding shares and institutions hold larger chunk of about 68.05% of that.
The stock has a current market capitalization of $14.02B and its 3Y-monthly beta is at 0.43. PE ratio of stock for trailing 12 months is 12.32, while it has posted earnings per share of $2.54 in the same period. Its PEG reads 3.85 and has Quick Ratio of 7.90 while making debt-to-equity ratio of 0.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.85% while standing at 2.59% over the month.
Analysts are in expectations that Royalty Pharma plc (RPRX) stock would likely to be making an EPS of $0.88 in the current quarter, while forecast for next quarter EPS is $0.88 and it is $4.09 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.81 which is $0.99 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $1.6 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -15.39% while it is estimated to increase by 13.90% in next year. EPS is likely to grow at an annualized rate of 3.20% for next 5-years, compared to annual growth of 2.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 14, 2022 offering a Buy rating for the stock and assigned a target price of $47 to it. Coverage by Scotiabank stated Royalty Pharma plc (RPRX) stock as a Sector outperform in their note to investors on May 13, 2022, suggesting a price target of $53 for the stock. On April 27, 2022, Goldman Initiated their recommendations, while on April 14, 2022, JP Morgan Upgrade their ratings for the stock with a price target of $50. Stock get an Overweight rating from Morgan Stanley on April 06, 2022.
